Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Zimmer Biomet : Announces Webcast and Conference Call of Third Quarter 2020 Financial Results

10/07/2020 | 11:22am EST

WARSAW, Ind. - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Friday, November 6, 2020, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be archived for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 312-9837 and entering conference ID 7278985. For a complete listing of international toll-free and local numbers, please visit https://investor.zimmerbiomet.com. A digital recording will be available after the completion of the conference call, from November 6, 2020 to January 10, 2021. To access the recording, U.S. callers should dial (888) 203-1112 and international callers should dial +1 (719) 457-0820, and enter the Access Code ID 7278985.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Media Contact

Meredith Weissman

703-346-3127

meredith.weissman@zimmerbiomet.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ZIMMER BIOMET HOLDINGS
12/01ZIMMER BIOMET : Foundation Launches, Supporting Diverse and Underserved Communit..
PR
12/01ZIMMER BIOMET : Completes Acquisition of A&E Medical Corporation
PR
11/18ZIMMER BIOMET : to Present at 2020 Evercore ISI HealthCONx Conference and Piper ..
AQ
11/17ZIMMER BIOMET : to Present at 2020 Evercore ISI HealthCONx Conference and Piper ..
PR
11/09ZIMMER BIOMET : Announces Third Quarter 2020 Financial Results
AQ
11/06ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
AQ
11/06ZIMMER : 3Q Earnings Snapshot
AQ
11/06ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
AQ
11/06ACELRX PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
AQ
11/06ZIMMER BIOMET : Announces Preliminary Results from mymobility Clinical Study at ..
AQ
More news
Financials (USD)
Sales 2020 7 058 M - -
Net income 2020 -170 M - -
Net Debt 2020 6 769 M - -
P/E ratio 2020 -181x
Yield 2020 0,65%
Capitalization 30 895 M 30 895 M -
EV / Sales 2020 5,34x
EV / Sales 2021 4,47x
Nbr of Employees 19 900
Free-Float 66,5%
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 157,44 $
Last Close Price 149,05 $
Spread / Highest target 17,4%
Spread / Average Target 5,63%
Spread / Lowest Target -28,9%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS-0.42%30 895
ABBOTT LABORATORIES24.22%184 876
MEDTRONIC PLC0.35%152 681
BECTON, DICKINSON AND COMPANY-10.74%70 408
HOYA CORPORATION23.88%46 370
ALIGN TECHNOLOGY, INC.86.97%41 138